Minutes of the 111th Meeting of the Council on Science and Technology for Health, Vaccinations and Vaccines Subcommittee, Adverse Events Investigation Committee, and the 1st Meeting of the Pharmaceutical Affairs and Food Sanitation Council, Committee on Safety Measures for Drugs, etc., Safety Measures Investigation Subcommittee (Joint Meeting) on April 22, Reiwa 8

SUMMARY

厚生労働省報道発表資料の報道によれば、「Minutes of the 111th Meeting of the Council on Science and Technology for Health, Vaccinations and Vaccines Subcommittee, Adverse Events Investigation Committee, and the 1st Meeting of the Pharmaceutical Affairs and Food Sanitation Council, Committee on Safety Measures for Drugs, etc., Safety Measures Investigation Subcommittee (Joint Meeting) on April 22, Reiwa 8」が伝えられています。医療業界の最新動向として、病院・クリニック・医療法人の経営判断に参考となる情報です。

📝 EDITOR'S NOTE — A Medical M&A Perspective

Trends in the medical industry directly impact the succession and M&A strategies of hospitals, clinics, and medical corporations. Changes in the complex management environment, such as revisions to medical fees, lack of successors, staffing shortages, burden of capital investment, and progress in regional medical plans, are forcing medical institutions to make new management decisions.

As an option for successor issues and changes in the management environment,Third-Party Succession M&Ais increasing in importance year by year. Choosing succession over closure or廃業 (business dissolution) allows for the simultaneous achievement of securing a transfer price, maintaining staff employment, ensuring continuity of patient care, and preserving regional medical services. The framework of M&A support institutions certified by the Small and Medium Enterprise Agency has also been established, and advisory services specializing in the unique licensing, tax, and labor issues of the medical industry have become widespread.

For medical institutions, accurately grasping industry trends and seeking early consultation with experts are key to attracting the best options for management decisions. As an M&A advisory firm specializing in the medical industry, we support medical institutions with free consultations and success-fee-based services.

News Highlights

The minutes of the joint meeting held on April 22, Reiwa 8, by the 111th Council on Science and Technology for Health, Vaccinations and Vaccines Subcommittee, Adverse Events Investigation Committee, and the 1st Pharmaceutical Affairs and Food Sanitation Council, Committee on Safety Measures for Drugs, etc., Safety Measures Investigation Subcommittee have been released. This meeting involved important discussions on the safety of vaccinations and pharmaceuticals.

M&A Medical Editorial Department’s Perspective

The joint meeting of the Council on Science and Technology for Health and the Pharmaceutical Affairs and Food Sanitation Council this time addressed two crucial themes that form the bedrock of the healthcare delivery system: the investigation of adverse events from vaccinations/vaccines and safety measures for pharmaceuticals. In particular, the rapid collection and response to information regarding adverse events, and the promotion of safe use of pharmaceuticals, are aspects of risk management that cannot be ignored in the operation of medical institutions. For example, when new vaccines are introduced, or when unexpected events occur even with approved pharmaceuticals, medical institutions are required to respond promptly and accurately from the perspective of accountability to patients and ensuring safety. This also serves as an important indicator for medical institutions considering M&A when evaluating post-succession risks. Especially for small and medium-sized medical institutions supporting regional healthcare, keeping up with the latest safety information and establishing/strengthening risk management systems based on it is indispensable from the perspective of business continuity. Understanding the latest regulatory trends and safety standards and incorporating them into M&A strategy leads to safer and more sustainable healthcare business succession.

Points Highlighted by This News

Grasping trends in adverse events from vaccinations and vaccines is directly linked to risk management for regional medical institutions.
Safety measure investigations for pharmaceuticals suggest the importance of compliance systems in medical institutions after succession.
The joint meeting emphasizes the need for a multifaceted perspective in healthcare safety.
The latest regulatory trends may affect the development of future business continuity plans (BCP) for medical institutions.

Practical Questions Arising from This News

What specific adverse event cases were particularly discussed at this meeting?
What specific measures should medical institutions take regarding the introduction of new vaccines or the safe use of existing pharmaceuticals?
What kind of regulatory changes might result from the discussions at the Pharmaceutical Affairs and Food Sanitation Council in the future?

If You Feel “Should I Consult Too?”

Are your vaccination and pharmaceutical handling’s latest safety information and associated risk management systems foolproof? Trends in safety, such as those discussed at the joint meeting of the Council on Science and Technology for Health and the Pharmaceutical Affairs and Food Sanitation Council, could affect future medical litigation risks and due diligence evaluation items in M&A. If you have concerns about gathering this information or establishing such systems, or if you wish to build a stronger business foundation when considering business succession through M&A, please consult with M&A specialists.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a completely success-fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here

📌 Source (Primary Information)

Minutes of the 111th Meeting of the Council on Science and Technology for Health, Vaccinations and Vaccines Subcommittee, Adverse Events Investigation Committee, and the 1st Meeting of the Pharmaceutical Affairs and Food Sanitation Council, Committee on Safety Measures for Drugs, etc., Safety Measures Investigation Subcommittee (Joint Meeting) on April 22, Reiwa 8

Source: Ministry of Health, Labour and Welfare Press Releases

Please see the original article for details

Regarding trends in medical institutions like this case,

we provide a detailed explanation of the 'Medical Succession Guide'

Read the Complete Guide →